San Mateo, CA, United States
San Mateo, CA, United States

Time filter

Source Type

Bio Simulation Technology Market is estimated at $1.01 billion in 2015 and is projected to reach $2.99 billion by 2022 growing at a CAGR of 16.6% from 2015 to 2022. Reduction in the cost of drug discovery and development and risk of failure of drug molecule are some of the factors driving the market growth. Furthermore, R&D investments in biotechnology and pharmaceutical industries, growth in the biologics and biosimilars markets, increased use of personalized medicines, technological advancements and periodic product upgradation are the key factors vitalizing the market growth. However, lack of standardization, high R&D costs associated with development of biosimulation software and lack of skilled professionals are some of the major restraints hampering the market growth. Industrial bioprocessing, nutraceuticals, agri-food production and biosimulation in the defense will provide opportunities for market growth over the forecast period. Pharmaceutical and biotechnology companies segment is valued to account largest share across the global market. North America is anticipated to command the largest share and Europe is expected to register the highest growth due to increasing government funding and the large number of pharmaceuticals and biotechnology companies in this region. Some of the key players in this market include Certara USA Inc., Simulation Plus Inc., Dassault Systèmes SA, Schrödinger Inc., Advanced Chemistry Development Inc., Chemical Computing Group Inc., Entelos Holding Corporation, Genedata Ag, Physiomics PLC, Rhenovia Pharma Ltd., Insilico biosciences, Archimedes, Insilico biotechnology, Accelrys, LeadScope and Compugen. Application Covered:  • Application In Drug Development  o Clinical Trials  o Preclinical Testing  • In Patient Validation  • Application In Drug Discovery  o Target Validation  o Target Identification  o Lead Identification/Discovery  o Lead Optimization Product Covered:  • Software  o Toxicity Prediction Software  o Molecular Modeling and Simulation Software  o Trial Design Software  o PK/PD Modeling and Simulation Software  o Pbpk Modeling and Simulation Software  o Other Software  • Services  o External/Contract Services  o In-House Services Regions Covered:  • North America  o US  o Canada  o Mexico  • Europe  o Germany  o France  o Italy  o UK  o Spain  o Rest of Europe  • Asia Pacific  o Japan  o China  o India  o Australia  o New Zealand  o Rest of Asia Pacific  • Rest of the World  o Middle East  o Brazil  o Argentina  o South Africa  o Egypt What our report offers:  - Market share assessments for the regional and country level segments  - Market share analysis of the top industry players  - Strategic recommendations for the new entrants  - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets  - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)  - Strategic recommendations in key business segments based on the market estimations  - Competitive landscaping mapping the key common trends  - Company profiling with detailed strategies, financials, and recent developments  - Supply chain trends mapping the latest technological advancements About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


This report studies the Global Biosimulation Market, analyzes and researches the Biosimulation development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Certara Simulation Plus Dassault Systèmes Schr?dinger Advanced Chemistry Development Chemical Computing Group Entelos Genedata Ag Physiomics PLC Rhenovia Pharma Market segment by Application, Biosimulation can be split into Application 1 Application 2 Application 3 United States, EU, Japan, China, India and Southeast Asia Biosimulation Market Size, Status and Forecast 2021 1 Industry Overview of Biosimulation 1.1 Biosimulation Market Overview 1.1.1 Biosimulation Product Scope 1.1.2 Market Status and Outlook 1.2 Global Biosimulation Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Biosimulation Market by End Users/Application 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 2 Global Biosimulation Competition Analysis by Players 2.1 Biosimulation Market Size (Value) by Players (2015-2016) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future 3 Company (Top Players) Profiles 3.1 Certara 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Biosimulation Revenue (Value) (2011-2016) 3.1.5 Recent Developments 3.2 Simulation Plus 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Biosimulation Revenue (Value) (2011-2016) 3.2.5 Recent Developments 3.3 Dassault Systèmes 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Biosimulation Revenue (Value) (2011-2016) 3.3.5 Recent Developments 3.4 Schr?dinger 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Biosimulation Revenue (Value) (2011-2016) 3.4.5 Recent Developments 3.5 Advanced Chemistry Development 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Biosimulation Revenue (Value) (2011-2016) 3.5.5 Recent Developments 3.6 Chemical Computing Group 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Biosimulation Revenue (Value) (2011-2016) 3.6.5 Recent Developments 3.7 Entelos 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Biosimulation Revenue (Value) (2011-2016) 3.7.5 Recent Developments 3.8 Genedata Ag 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Biosimulation Revenue (Value) (2011-2016) 3.8.5 Recent Developments 3.9 Physiomics PLC 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Biosimulation Revenue (Value) (2011-2016) 3.9.5 Recent Developments 3.10 Rhenovia Pharma 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Biosimulation Revenue (Value) (2011-2016) 3.10.5 Recent Developments For more information or any query mail at [email protected]


Ragkousi K.,University of Arizona | Beh J.,University of California at Berkeley | Beh J.,Entelos | Sweeney S.,University of Arizona | And 3 more authors.
Developmental Biology | Year: 2011

GATA family transcription factors are core components of the vertebrate heart gene network. GATA factors also contribute to heart formation indirectly through regulation of endoderm morphogenesis. However, the precise impact of GATA factors on vertebrate cardiogenesis is masked by functional redundancy within multiple lineages. Early heart specification in the invertebrate chordate Ciona intestinalis is similar to that of vertebrates but only one GATA factor, Ci-GATAa, is expressed in the heart progenitor cells and adjacent endoderm. Here we delineate precise, tissue specific contributions of GATAa to heart formation. Targeted repression of GATAa activity in the heart progenitors perturbs their transcriptional identity. Targeted repression of endodermal GATAa function disrupts endoderm morphogenesis. Subsequently, the bilateral heart progenitors fail to fuse at the ventral midline. The resulting phenotype is strikingly similar to cardia bifida, as observed in vertebrate embryos when endoderm morphogenesis is disturbed. These findings indicate that GATAa recapitulates cell-autonomous and non-cell-autonomous roles performed by multiple, redundant GATA factors in vertebrate cardiogenesis. © 2011 .


News Article | November 22, 2016
Site: www.newsmaker.com.au

Biosimulation refers to a process involving simulation of biological processes with the help of computer sided mathematical models. Biosimulation is an integral part of systems biology and helps in clinical drug development, drug metabolism and modeling of complex biomedical systems. Need for reduction in the cost of drug discovery and development and risk of failure of drug molecule in the late phase are some of the main factors which help to drive the market. On the basis of application, biosimulation market can be segmented into drug discovery and drug development. Drug discovery includes target identification, target validation, lead identification and lead optimization. Target identification includes protein structure prediction, target validation includes protein modeling software, lead identification includes de novo design and lead optimization includes quantitative structure-activity relationship (QSAR) models. Drug development includes pre-clinical testing, clinical trials and in-patient validation. Pre-clinical testing includes ADME/tox prediction, pharmacokinetic/pharmacodynamic (PK/PD) models and clinical trials includes phase I clinical trial, phase II clinical trial and phase III clinical trial. North America, followed by Europe, has the largest market for biosimulation due to developed healthcare infrastructure, technological advancement, rise in spending on healthcare, off patenting of many drugs and need for novel modeling and simulation tools in this region. In additional, Europe is expected to experience high growth rate in the biosimulation market in next few years due to government support, growing research and development activities, increasing demand for technological advancement in drug discovery and development and rise in healthcare expenditure in the region. Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/3726 Growing demand for reduction in drug discovery and development cost, increasing incidence of chronic diseases, rise in need for new techniques for drug discovery process, increasing healthcare expenditure and improved modeling and simulation tools are some of the major factors driving the global market for biosimulation. In addition, risk of failure in the late drug development stages, time consuming traditional drug discovery and development procedure, rise in the demand for better healthcare facilities, government initiatives for promoting new tools and techniques in drug discovery and development process and increasing number of research and development activities are driving the global market for biosimulation. However, lack of standardization, high R&D costs associated with development of biosimulation software and lack of skilled professionals are some of the major factors restraining the growth for global biosimulation market. Broader application of biosimulation in drug discovery and development, continuous rise in the demand for advanced software programs and improved simulation technology and emerging market are expected to offer new opportunities for global biosimlation market. Issues associated with accuracy in prediction and interoperability issues are some of the challenges faced by the global biosimulation market. Increasing collaborations and partnerships, patient medication, rise in mergers and acquisition, drug repositioning, modeling and simulations in paediatrics dug development and new product launches along with technological advancement are some of the latest trends that have been observed in global biosimulation market. Some of the major companies operating in the global biosimulation market are Accelrys, Simulation plus, Genedata, LeadScope, Rhenovia, Entelos and ACD/Labs. In addition some other companies having significant presence in the global biosimulation market are Schrodinger, Physiomics, Insilico biosciences and Archimedes.


News Article | December 7, 2016
Site: marketersmedia.com

RICHMOND, VA / ACCESSWIRE / December 7, 2016 / Exactus, Inc. (OTCQB: EXDI), a life science company that is developing and commercializing ultra-fast, handheld, point-of-care (POC) diagnostic tools powering informed patient management, announced today the appointment of James R. Erickson, Ph.D. as Chief Business Officer. Dr. Erickson will report to Philip J. Young, President and CEO of Exactus. James started his career as a post-doc at Onyx Pharmaceuticals and has since worked primarily in business development roles for diagnostic and biopharmaceutical companies, including AGY Therapeutics, Entelos and Titan Pharmaceuticals. In 2005 Dr. Erickson founded BayPoint Biosystems, a proteomic company focused on commercializing diagnostics/research tools-oriented technology from the M.D. Anderson Cancer Center. From 2005-2013, BayPoint established biomarker discovery and companion diagnostic development alliances with 12 pharmaceutical, biotechnology, and life science companies. Immediately prior to joining Exactus, James worked as Senior Transaction Advisor at Ferghana Partners, a healthcare investment bank focusing on financings, M&A, and corporate partnering in the diagnostic and therapeutic sectors. "We are fortunate to have an executive with such a broad background in developing novel diagnostic platforms," said Mr. Young. "James' experience in both the technical as well as the transactional aspects of bringing diagnostic to fruition will be an important addition to our management team. We are excited to have James on board as the Company advances towards commercialization of the FibriLyzer™ platform." Exactus is a publicly traded life science company based in Richmond, Virginia that is developing and commercializing point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibriLyzer™, will provide a simple and affordable means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibriLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and saving money. Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been proven to be an early hallmark of cancer. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information about Exactus, please visit our website at: www.exactusdx.com. This press release and any statements of representatives and partners of Exactus, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the actual timing for, or actual results of, the Company's clinical trial described herein or the FDA's review of such results) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. RICHMOND, VA / ACCESSWIRE / December 7, 2016 / Exactus, Inc. (OTCQB: EXDI), a life science company that is developing and commercializing ultra-fast, handheld, point-of-care (POC) diagnostic tools powering informed patient management, announced today the appointment of James R. Erickson, Ph.D. as Chief Business Officer. Dr. Erickson will report to Philip J. Young, President and CEO of Exactus. James started his career as a post-doc at Onyx Pharmaceuticals and has since worked primarily in business development roles for diagnostic and biopharmaceutical companies, including AGY Therapeutics, Entelos and Titan Pharmaceuticals. In 2005 Dr. Erickson founded BayPoint Biosystems, a proteomic company focused on commercializing diagnostics/research tools-oriented technology from the M.D. Anderson Cancer Center. From 2005-2013, BayPoint established biomarker discovery and companion diagnostic development alliances with 12 pharmaceutical, biotechnology, and life science companies. Immediately prior to joining Exactus, James worked as Senior Transaction Advisor at Ferghana Partners, a healthcare investment bank focusing on financings, M&A, and corporate partnering in the diagnostic and therapeutic sectors. "We are fortunate to have an executive with such a broad background in developing novel diagnostic platforms," said Mr. Young. "James' experience in both the technical as well as the transactional aspects of bringing diagnostic to fruition will be an important addition to our management team. We are excited to have James on board as the Company advances towards commercialization of the FibriLyzer™ platform." Exactus is a publicly traded life science company based in Richmond, Virginia that is developing and commercializing point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibriLyzer™, will provide a simple and affordable means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibriLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and saving money. Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been proven to be an early hallmark of cancer. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information about Exactus, please visit our website at: www.exactusdx.com. This press release and any statements of representatives and partners of Exactus, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the actual timing for, or actual results of, the Company's clinical trial described herein or the FDA's review of such results) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.


Murray C.,Trinity College Dublin | Huerta-Sanchez E.,University of California at Berkeley | Casey F.,Entelos | Bradley D.G.,Trinity College Dublin
Philosophical Transactions of the Royal Society B: Biological Sciences | Year: 2010

The phylogeography of cattle genetic variants has been extensively described and has informed the history of domestication. However, there remains a dearth of demographic models inferred from such data. Here, we describe sequence diversity at 37 000 bp sampled from 17 genes in cattle from Africa, Europe and India. Clearly distinct population histories are suggested between Bos indicus and Bos taurus, with the former displaying higher diversity statistics. We compare the unfolded site frequency spectra in each to those simulated using a diffusion approximation method and build a best-fitting model of past demography. This implies an earlier, possibly glaciation-induced population bottleneck in B. taurus ancestry with a later, possibly domestication-associated demographic constriction in B. indicus. Strikingly, the modelled indicine history also requires a majority secondary admixture from the South Asian aurochs, indicating a complex, more diffuse domestication process. This perhaps involved multiple domestications and/or introgression from wild oxen to domestic herds; the latter is plausible from archaeological evidence of contemporaneous wild and domestic remains across different regions of South Asia. © 2010 The Royal Society.


Schmidt B.J.,Entelos | Casey F.P.,Entelos | Paterson T.,Entelos | Chan J.R.,Entelos
BMC Bioinformatics | Year: 2013

Background: Mechanistic biosimulation can be used in drug development to form testable hypotheses, develop predictions of efficacy before clinical trial results are available, and elucidate clinical response to therapy. However, there is a lack of tools to simultaneously (1) calibrate the prevalence of mechanistically distinct, large sets of virtual patients so their simulated responses statistically match phenotypic variability reported in published clinical trial outcomes, and (2) explore alternate hypotheses of those prevalence weightings to reflect underlying uncertainty in population biology. Here, we report the development of an algorithm, MAPEL (Mechanistic Axes Population Ensemble Linkage), which utilizes a mechanistically-based weighting method to match clinical trial statistics. MAPEL is the first algorithm for developing weighted virtual populations based on biosimulation results that enables the rapid development of an ensemble of alternate virtual population hypotheses, each validated by a composite goodness-of-fit criterion.Results: Virtual patient cohort mechanistic biosimulation results were successfully calibrated with an acceptable composite goodness-of-fit to clinical populations across multiple therapeutic interventions. The resulting virtual populations were employed to investigate the mechanistic underpinnings of variations in the response to rituximab. A comparison between virtual populations with a strong or weak American College of Rheumatology (ACR) score in response to rituximab suggested that interferon β (IFNβ) was an important mechanistic contributor to the disease state, a signature that has previously been identified though the underlying mechanisms remain unclear. Sensitivity analysis elucidated key anti-inflammatory properties of IFNβ that modulated the pathophysiologic state, consistent with the observed prognostic correlation of baseline type I interferon measurements with clinical response. Specifically, the effects of IFNβ on proliferation of fibroblast-like synoviocytes and interleukin-10 synthesis in macrophages each partially counteract reductions in synovial inflammation imparted by rituximab. A multianalyte biomarker panel predictive for virtual population therapeutic responses suggested population dependencies on B cell-dependent mediators as well as additional markers implicating fibroblast-like synoviocytes.Conclusions: The results illustrate how the MAPEL algorithm can leverage knowledge of cellular and molecular function through biosimulation to propose clear mechanistic hypotheses for differences in clinical populations. Furthermore, MAPEL facilitates the development of multianalyte biomarkers prognostic of patient responses in silico. © 2013 Schmidt et al.; licensee BioMed Central Ltd.


Patent
Entelos | Date: 2010-12-14

Methods and apparatus to identify a potential toxicity of a therapy in a biological system are described. In one embodiment, a method uses a computer model that represents a set of biological processes of the biological system. The method includes executing the computer model to identify a first set of biological processes contributing to the occurrence of a toxic state of the biological system. The method also includes identifying a set of biological assays based on the first set of biological processes and testing the therapy in the set of biological assays to identify a second set of biological processes modified by the therapy. The method further includes identifying the potential toxicity of the therapy based on the second set of biological processes.


(http://www.researchandmarkets.com/research/dl9gbg/admetoxicology) has announced the addition of the "ADME-Toxicology Testing - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ Million by the following Segments: Toxicology Testing (In-Vivo, & In-Vitro), and ADME Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 73 companies including many key and niche players such as:

Loading Entelos collaborators
Loading Entelos collaborators